Metavia Inc MTVA

$1.01 -0.06 (-5.61%)

Valuation

Market cap
6,810,000
Revenue TTM
$0
Net income TTM
$-12,970,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
39,500
Avg volume
115,182
Day's range
$1.00 – $1.10
Shares out
6,743,000
Stochastic %K
2%
Beta
1.24
Analysts
Strong Buy
Price target
$17.67

Price

Company profile

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 cli...

Show more

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
857 702 9600
Website
https://www.metaviatx.com
Address
545 Concord Avenue, Suite 210, Cambridge, United States

Latest news

Stocktwits

Kertzi Nov 20, 1:25 PM
$MTVA The Dong-A (Korea) risk nobody seems to be discussing. MetaVia reportedly owes Dong-A ST approximately $2.1 million, including overdue invoices and accrued clinical costs. Dong-A is not just a major shareholder — it is also a key supplier, the original developer and the licensor of both drug candidates. What happens if Dong-A decides it has had enough? It could demand payment and, if contractual conditions are met, suspend services or terminate agreements. Losing Dong-A's support could seriously disrupt the development of both assets. With cash running low, Nasdaq's minimum equity requirement already breached, and no clear financing solution in sight, this is a serious risk shareholders should not ignore. Could Dong-A be MetaVia's biggest lifeline — or ultimately the reason this company runs out of road?
0 replies
Joefreeagent Nov 19, 10:05 AM
$MTVA On November 17, 2026, MetaVia Inc. (the “Company”) received written notice from the Nasdaq Stock Market (“Nasdaq”) stating that the Company no longer complies with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) for continued listing on The Nasdaq Capital Market because the Company’s stockholders’ equity, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, has fallen below $2.5 million. The notice also indicates that the Company does not meet the alternative compliance standards. SCAM.. SCAM..SCAM!
0 replies
Kertzi Nov 18, 11:41 PM
$MTVA ANNUAL TRADITION, DELISTING WARNING TO KOREAN SCAM https://www.sec.gov/Archives/edgar/data/1638287/000110465926129393/mtva-20261117x8k.htm Can they actually raise enough new capital to keep this Ponzi operation alive, or will Dong-A finally pull the plug?
0 replies
Kertzi Nov 17, 10:17 AM
$MTVA MASSIVE DILUTION AHEAD. BANKRUPTCY RISK CANNOT BE RULED OUT. The company has cash runway only into Q1 2027, according to its own investor presentation. Reverse split → ATM / new offering → warrants → massive dilution. Look at the shareholder value destruction since 2017... Horrible.
0 replies
BarryJets Nov 17, 4:23 AM
$MTVA Potential obesity and metabolic disease treatments.
0 replies
BarryJets Nov 17, 4:23 AM
$MTVA Positive Phase 1 clinical trial results for DA-1726..
0 replies
focafoca99 Nov 16, 2:27 PM
$MTVA illustrates positive preclinical data for DA-1726, a dual OXM analog beating retatrutide in weight-loss and metabolic studies.
0 replies
RobbysInvestmentLLC Nov 16, 1:46 PM
$MTVA i thought they loved these GLP 1 tickers!? Keep on watch incase volume comes in 👀
0 replies